Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00683826 · ClinicalTrials.gov registry record · NA

The Effects of Leucine on Body Weight

A NA study of Obesity and Overweight, sponsored by Columbia University.

Completed
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT00683826 is a NA study of Obesity and Overweight that has completed, run by Columbia University. The registered enrollment target is 8 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00683826, a NA study of Obesity and Overweight, has completed, sponsored by Columbia University.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Protein-rich diets appear to show some benefits in promoting weight loss. It is thought that increased intake of leucine may account for some of this effect. This study is designed to assess whether any of the beneficial effects of dietary leucine supplementation observed in mice also apply to humans. Specifically, our team would like to determine whether oral leucine supplementation in overweight/obese humans increases metabolic rate, reduces body weight, improves glucose utilization and/or, reduces circulating fat levels in the blood. We hope that the results obtained from this pilot study will highlight the specific aspects of metabolic improvement associated with increased daily leucine intake. This study will should provide data that can be used to design more definitive trials with regard to dietary leucine supplementation. Hypothesis This pilot study is designed to accomplish the following two goals: 1. to assess whether any of the beneficial effects of dietary leucine supplementation observed in mice also apply in humans. Specifically, we want to determine whether oral leucine supplementation in overweight/obese individuals' increases basal metabolic rate, reduces body weight, improves glucose tolerance and/or insulin sensitivity, and/or reduces circulating Low-density Lipoprotein (LDL)-cholesterol levels. 2. To provide data that can be used to design more definitive trials with regard to dietary leucine supplementation. We hope that the results obtained from this pilot study will highlight the specific aspects of metabolic improvement associated with increased daily leucine intake. This would in turn lead to more rigorous clinical trials involving larger sample sizes, and with diverse populations of different gender, age, and ethnic groups. Future trials may also be directed to determine minimal doses and durations of leucine supplementation that are capable of achieving clinically significant improvement in the cardio-metabolic risk profile in people.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT L-Leucine 8gr
  • OTHER Liquid meal
  • DIETARY_SUPPLEMENT L-Leucine 4g

Study Locations (1)

New York

  • Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2007-05
Est. Completion 2010-02
Phase NA

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT00683826

The ClinicalTrials.gov registry entry for NCT00683826 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which L-Leucine 8gr is the first listed.

NCT00683826 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00683826 about?

NCT00683826 is a clinical study titled "The Effects of Leucine on Body Weight". Protein-rich diets appear to show some benefits in promoting weight loss. It is thought that increased intake of leucine may account for some of this effect. This study is designed to assess whether any of the beneficial effects of dietary leucine supplementation observed in mice also apply to human...

What is the current status of trial NCT00683826?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2007-05. Estimated completion is 2010-02.

What conditions does trial NCT00683826 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT00683826?

The interventions under investigation include: L-Leucine 8gr (DIETARY_SUPPLEMENT), Liquid meal (OTHER), L-Leucine 4g (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00683826?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00683826 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.